IDEXX Laboratories, Inc. $IDXX Stock Bought by MGO One Seven LLC

Posted by Brian Himes on Nov 4th, 2026

MGO One Seven LLC increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 288.1% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 5,566 shares of the company’s stock after purchasing an additional 4,132 shares during the quarter. MGO One Seven LLC’s holdings in IDEXX Laboratories were worth $2,907,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Aurora Investment Managers LLC. bought a new stake in IDEXX Laboratories during the 2nd quarter valued at approximately $2,442,000. National Pension Service boosted its stake in IDEXX Laboratories by 5.6% during the second quarter. National Pension Service now owns 129,305 shares of the company’s stock worth $68,071,000 after buying an additional 6,885 shares in the last quarter. NewEdge Advisors LLC boosted its position in shares of IDEXX Laboratories by 60.9% during the 1st quarter. NewEdge Advisors LLC now owns 15,221 shares of the company’s stock valued at $8,552,000 after acquiring an additional 5,761 shares in the last quarter. Arizona State Retirement System boosted its holdings in IDEXX Laboratories by 4.9% during the second quarter. Arizona State Retirement System now owns 22,772 shares of the company’s stock valued at $11,988,000 after purchasing an additional 1,074 shares in the last quarter. Finally, Howard Capital Management LLC acquired a new stake in IDEXX Laboratories in the 3rd quarter valued at $1,249,000. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Price Performance

NASDAQ IDXX opened at $672.04 on Wednesday. The firm’s 50 day moving average is $538.81 and its 200-day moving average is $573.69. The company has a quick ratio of 0.87, a current ratio of 1.19 and a debt-to-equity ratio of 0.16. IDEXX Laboratories, Inc. has a 12-month low of $500.61 and a 12-month high of $769.98. The company has a market capitalization of $52.94 billion, a PE ratio of 45.32 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last posted its quarterly earnings data on Monday, November 2nd. The company reported $3.96 EPS for the quarter, topping analysts’ consensus estimates of $3.71 by $0.25. IDEXX Laboratories had a net margin of 25.36% and a return on equity of 71.04%. The company had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.19 billion. During the same period in the prior year, the business posted $3.22 EPS. The company’s quarterly revenue was up 9.9% on a year-over-year basis. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post 15.05 earnings per share for the current fiscal year.

IDEXX Laboratories News Summary

Here are the key news stories impacting IDEXX Laboratories this week:

Positive Sentiment: Third-quarter results beat expectations: IDEXX reported adjusted earnings of $3.96 per share versus $3.71 expected, while revenue rose about 10% year over year to $1.21 billion, above estimates. Recurring diagnostics sales to veterinarians were a key growth driver. IDXX Q3 Earnings & Revenues Surpass Estimates
Positive Sentiment: The company raised its full-year 2026 outlook, projecting EPS of $14.96–$15.16, above the $14.86 consensus, and revenue of $4.7–$4.8 billion, versus expectations of about $4.7 billion. The higher forecast reinforces optimism after the quarterly beat. IDEXX raises forecast
Positive Sentiment: Morgan Stanley maintained an Overweight/Buy view and raised its price target to $810, signaling further potential upside in the analyst’s assessment. Morgan Stanley stock recommendations
Positive Sentiment: A technical analysis report said IDXX moved above its 200-day moving average, a signal some investors interpret as supportive of a longer-term upward trend. IDXX crossed above the 200-day moving average
Negative Sentiment: Analysts noted that veterinary visits remain lackluster, creating a challenging demand backdrop. IDEXX’s results were strong despite this, but the company is relying on diagnostics growth to offset softer visit trends. UBS on IDEXX’s results and vet-visit backdrop

Insider Buying and Selling

In other news, Director Lawrence D. Kingsley sold 2,203 shares of IDEXX Laboratories stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $532.08, for a total value of $1,172,172.24. Following the completion of the transaction, the director owned 9,568 shares of the company’s stock, valued at $5,090,941.44. This trade represents a 18.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.79% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several analysts have weighed in on IDXX shares. BTIG Research dropped coverage on shares of IDEXX Laboratories in a research note on Friday, October 30th. They set a “buy” rating on the stock. Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Morgan Stanley lifted their target price on shares of IDEXX Laboratories from $805.00 to $810.00 and gave the stock an “overweight” rating in a report on Tuesday. KeyCorp assumed coverage on IDEXX Laboratories in a research report on Monday, October 12th. They set a “sector weight” rating for the company. Finally, Leerink Partners lowered their price objective on shares of IDEXX Laboratories from $725.00 to $715.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Seven equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $719.55.

Read Our Latest Research Report on IDXX

IDEXX Laboratories Profile

(Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.